RU2116300C1 - Производные имидазола или их физиологически совместимые соли, способ их получения, средство для снижения высокого давления крови и фармацевтическая композиция для снижения кровяного давления - Google Patents

Производные имидазола или их физиологически совместимые соли, способ их получения, средство для снижения высокого давления крови и фармацевтическая композиция для снижения кровяного давления Download PDF

Info

Publication number
RU2116300C1
RU2116300C1 RU93004577A RU93004577A RU2116300C1 RU 2116300 C1 RU2116300 C1 RU 2116300C1 RU 93004577 A RU93004577 A RU 93004577A RU 93004577 A RU93004577 A RU 93004577A RU 2116300 C1 RU2116300 C1 RU 2116300C1
Authority
RU
Russia
Prior art keywords
general formula
compound
alkyl
mmol
imidazole
Prior art date
Application number
RU93004577A
Other languages
English (en)
Russian (ru)
Other versions
RU93004577A (ru
Inventor
Хайч Холгер
Хеннинг Раинер
Вагнер Адальберт
Герхардс Херманн
Бекер Райнхард
Шелькенс Бернвард
Original Assignee
Хехст АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хехст АГ filed Critical Хехст АГ
Publication of RU93004577A publication Critical patent/RU93004577A/ru
Application granted granted Critical
Publication of RU2116300C1 publication Critical patent/RU2116300C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
RU93004577A 1992-03-07 1993-03-05 Производные имидазола или их физиологически совместимые соли, способ их получения, средство для снижения высокого давления крови и фармацевтическая композиция для снижения кровяного давления RU2116300C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07
DEP4207241.7 1992-03-07

Publications (2)

Publication Number Publication Date
RU93004577A RU93004577A (ru) 1996-02-27
RU2116300C1 true RU2116300C1 (ru) 1998-07-27

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93004577A RU2116300C1 (ru) 1992-03-07 1993-03-05 Производные имидазола или их физиологически совместимые соли, способ их получения, средство для снижения высокого давления крови и фармацевтическая композиция для снижения кровяного давления

Country Status (25)

Country Link
US (1) US5604251A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0560177B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3542813B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR930019637A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1036341C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE230732T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU663565B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9300761A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2091135A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ281983B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE59310323D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0560177T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2187501T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI930970A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT64041A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL104971A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA22814A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO303632B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ247059A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31466A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL173023B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2116300C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK279109B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW215434B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA931585B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
WO1997029747A1 (en) 1996-02-20 1997-08-21 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US6022887A (en) * 1996-12-13 2000-02-08 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
EP0855392A3 (de) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP2001520170A (ja) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｆ−ａｔ３機能に関連した心肥大動物モデルと治療法
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL144708A0 (en) 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US20040082613A1 (en) * 2002-06-28 2004-04-29 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
CN1812776A (zh) * 2003-05-21 2006-08-02 得克萨斯州大学系统董事会 抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) * 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
CA2544772A1 (en) * 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
ATE407925T1 (de) * 2003-11-03 2008-09-15 Myogen Inc 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
AU2004299058A1 (en) * 2003-12-12 2005-06-30 Aventis Pharmaceutical, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2005092332A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
WO2005092333A1 (en) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
CA2572179A1 (en) * 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20090220507A1 (en) * 2005-07-22 2009-09-03 Sucharov Carmen C Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
US20090306373A1 (en) * 2005-12-20 2009-12-10 Gamber Gabriel G 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
CA2659364C (en) 2006-08-01 2017-08-22 Board Of Regents Of The University Of Texas System Identification of a micro-rna that activates expression of .beta.-myosin heavy chain
BRPI0815383A2 (pt) 2007-07-31 2015-09-08 Univ Texas família de micro-rna que modula fibrose e usos da mesma
JP5653899B2 (ja) 2008-03-17 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 神経筋シナプスの維持および再生に関与するマイクロｒｎａの同定
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000068A1 (en) * 1990-06-28 1992-01-09 Smithkline Beecham Corporation Substituted histidines
SU1518949A1 (ru) * 1987-04-09 1995-04-30 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получения инъекционного раствора 5-этокси-2-этилтиобензимидазола

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (en) * 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
AU2496492A (en) * 1991-08-19 1993-03-16 E.I. Du Pont De Nemours And Company Angiotensin ii receptor blocking imidazolinone derivatives
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
JP3501484B2 (ja) * 1992-12-17 2004-03-02 三共株式会社 ビフェニル誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1518949A1 (ru) * 1987-04-09 1995-04-30 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получения инъекционного раствора 5-этокси-2-этилтиобензимидазола
WO1992000068A1 (en) * 1990-06-28 1992-01-09 Smithkline Beecham Corporation Substituted histidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
3. GB, патент, 2142533, A, A 61 K 31/ 415, 23.01.88. *

Also Published As

Publication number Publication date
CZ381192A3 (en) 1993-12-15
PL297955A1 (en) 1993-09-20
PH31466A (en) 1998-11-03
CZ281983B6 (cs) 1997-04-16
AU663565B2 (en) 1995-10-12
FI930970A0 (fi) 1993-03-04
PL173023B1 (pl) 1998-01-30
NZ247059A (en) 1995-03-28
ATE230732T1 (de) 2003-01-15
TW215434B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-11-01
US5604251A (en) 1997-02-18
HUT64041A (en) 1993-11-29
ZA931585B (en) 1993-09-27
EP0560177A1 (de) 1993-09-15
HU9300618D0 (en) 1993-05-28
AU3401193A (en) 1993-09-09
MA22814A1 (fr) 1993-10-01
EP0560177B1 (de) 2003-01-08
BR9300761A (pt) 1993-09-14
FI930970A7 (fi) 1993-09-08
DE59310323D1 (de) 2003-02-13
CN1076192A (zh) 1993-09-15
SK381192A3 (en) 1998-06-03
ES2187501T3 (es) 2003-06-16
NO930817D0 (no) 1993-03-05
CA2091135A1 (en) 1993-09-08
CN1036341C (zh) 1997-11-05
JP3542813B2 (ja) 2004-07-14
IL104971A0 (en) 1993-07-08
NO930817L (no) 1993-09-08
JPH069572A (ja) 1994-01-18
NO303632B1 (no) 1998-08-10
KR930019637A (ko) 1993-10-18
DK0560177T3 (da) 2003-04-14
SK279109B6 (sk) 1998-06-03

Similar Documents

Publication Publication Date Title
RU2116300C1 (ru) Производные имидазола или их физиологически совместимые соли, способ их получения, средство для снижения высокого давления крови и фармацевтическая композиция для снижения кровяного давления
RU2047604C1 (ru) Замещенные азолы и способ их получения
RU2076105C1 (ru) Имидазо-аннелированные изо- и гетероциклы и способ их получения
US5162326A (en) Pyrimidinedione derivatives, their production and use
AU653760B2 (en) Azole derivatives, process for their preparation, and their use
CZ282142B6 (cs) Cykloalkylsubstituované glutaramidové deriváty, farmaceutický prostředek obsahující tyto sloučeniny a použití
HUT64057A (en) Process for producing sulfonylbenzyl-substituted pyridone derivatives and pahrmaceutical compositions comprising same
EP0430300A2 (en) Xanthine derivatives, their production and use
EP0434038A1 (en) Fused imidazole derivatives, their production and use
HUT61984A (en) Process for producing condensed imidazole derivatives and pharmaceutical compositions comprising same
NO303541B1 (no) Substituerte bifenylpyridoner og deres anvendelse til fremstilling av legemidler
KR20020012207A (ko) 안지오텐신(1-7) 수용체 작용제로서의1-(ｐ-티에닐벤질)이미다졸, 이의 제조방법, 이의 용도 및이를 포함하는 약제학적 제제
HUT70485A (en) Substituted mono- and bipyridyl-methyl-pyridone derivatives and process for producing them
EP0443568A1 (en) Fused thiophene derivatives, their production and use
RU2233278C2 (ru) Пиримидиновые соединения, способ их получения и фармацевтическая композиция
US20040127533A1 (en) Sulfonamide derivatives
HUT62576A (en) Process for producing substituted imidazolylpropenoic acid derivatives and pharmaceutical compositions comprising such compounds
US8063090B2 (en) Mineralocorticoid receptor modulators
JP2002510623A (ja) 抗糖尿病薬
US5576327A (en) Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds
HUT62577A (en) Process for producing imidazolylpropenoic acid derivatives and pharmaceutical compositions comprising same
RU2104272C1 (ru) Производные имидазола, способ их получения и фармацевтическая композиция, понижающая кровяное давление
JP3116256B2 (ja) （チオ）ウレア誘導体
KR20220156890A (ko) Phd 억제제 화합물, 조성물, 및 용도
IL296631A (en) Phd inhibitor compounds, compositions, and use